Compare Recursion Pharmaceuticals Inc (RXRX) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Charles Schwab Corporation Common Stock — how do they compare? Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B), while Charles Schwab Corporation Common Stock trades at $100.04 (market cap $178.33B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 116.6× Recursion Pharmaceuticals Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.25% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SCHW | |
|---|---|---|
Market Cap | $1.53B | $178.33B |
Sector | Health | Financials |
52-Week High | $6.79 | $107.21 |
52-Week Low | $2.84 | $85.35 |
Enterprise Value | $946.50M | — |
Dividend Yield | — | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Charles Schwab (SCHW) trades at $99.96, down 1.58% on the day, amid strong fundamentals including a 37.99% net income margin and 21.79% ROE. The stock exhibits a bullish technical trend with moving averages supporting upside, while oscillators are neutral. Recent Q2 2026 earnings beat expectations with EPS of $1.62 versus $1.53 estimated, driven by record revenue and client asset growth. Analyst consensus is bullish with a $120 price target, reflecting 20% upside potential.
Outlook remains positive given consistent earnings beats and robust cash flow, though risks include interest rate sensitivity and competitive pressures. The stock's current valuation at a P/E of 20.39 appears reasonable relative to growth, supporting a favorable risk-reward profile for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
